These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 20855866)

  • 21. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
    Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
    J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells.
    Cardona ME; Simonson OE; Oprea II; Moreno PM; Silva-Lara MF; Mohamed AJ; Christensson B; Gahrton G; Dilber MS; Smith CI; Arteaga HJ
    Leuk Lymphoma; 2016; 57(1):183-92. PubMed ID: 25907616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.
    Rommer A; Steinmetz B; Herbst F; Hackl H; Heffeter P; Heilos D; Filipits M; Steinleitner K; Hemmati S; Herbacek I; Schwarzinger I; Hartl K; Rondou P; Glimm H; Karakaya K; Krämer A; Berger W; Wieser R
    PLoS One; 2013; 8(2):e56308. PubMed ID: 23457546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.
    Vázquez I; Maicas M; Marcotegui N; Conchillo A; Guruceaga E; Roman-Gomez J; Calasanz MJ; Agirre X; Prosper F; Odero MD
    Proc Natl Acad Sci U S A; 2010 Nov; 107(44):E167-8; author reply E169-70. PubMed ID: 20930122
    [No Abstract]   [Full Text] [Related]  

  • 25. Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Löwenberg B; Delwel R
    Exp Hematol; 2003 Nov; 31(11):1066-72. PubMed ID: 14585371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
    Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
    Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EVI1 up-regulates the stress responsive gene SIRT1 which triggers deacetylation and degradation of EVI1.
    Pradhan AK; Kuila N; Singh S; Chakraborty S
    Biochim Biophys Acta; 2011; 1809(4-6):269-75. PubMed ID: 21555002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
    Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
    Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response.
    Bingemann SC; Konrad TA; Wieser R
    FEBS J; 2009 Nov; 276(22):6810-22. PubMed ID: 19843176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.
    Yamakawa N; Kaneda K; Saito Y; Ichihara E; Morishita K
    PLoS One; 2012; 7(1):e30706. PubMed ID: 22295105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
    Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Shiba N; Ohki K; Hayashi Y; Yamashita Y; Shimada A; Tanaka S; Adachi S
    Haematologica; 2014 Nov; 99(11):e225-7. PubMed ID: 25015941
    [No Abstract]   [Full Text] [Related]  

  • 34. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.
    Ho PA; Alonzo TA; Gerbing RB; Pollard JA; Hirsch B; Raimondi SC; Cooper T; Gamis AS; Meshinchi S
    Br J Haematol; 2013 Sep; 162(5):670-7. PubMed ID: 23826732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal.
    Paredes R; Kelly JR; Geary B; Almarzouq B; Schneider M; Pearson S; Narayanan P; Williamson A; Lovell SC; Wiseman DH; Chadwick JA; Jones NJ; Kustikova O; Schambach A; Garner T; Amaral FMR; Pierce A; Stevens A; Somervaille TCP; Whetton AD; Meyer S
    Cell Death Dis; 2020 Oct; 11(10):878. PubMed ID: 33082307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [EVI1 expression, clinical and cytogenetical characteristics in 447 patients with acute myeloid leukemia].
    He XF; Wang QR; Cen JN; Qiu HY; Sun AN; Chen SN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):936-941. PubMed ID: 27995876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
    Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
    Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
    PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.
    Weisser M; Kern W; Schoch C; Tschulik C; Hiddemann W; Haferlach T; Schnittger S
    Leuk Lymphoma; 2006 Dec; 47(12):2645-7. PubMed ID: 17169810
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.